Condition: Diphtheria-Tetanus-acellular Pertussis Vaccines · Sponsor: GlaxoSmithKline
The purpose of the study is to assess the immune response, reactogenicity and safety of a booster dose of dTpa vaccine 1 month after vaccination in healthy Japanese participants aged 11 to \<13 years.
This description comes directly from the study's public registry record.
US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
Always discuss trial participation with your own doctor first.
| GSK Investigational Site | Fukuoka, Japan | Recruiting |
| GSK Investigational Site | Hokkaido, Japan | Recruiting |
| GSK Investigational Site | Hokkaido, Japan | Recruiting |
| GSK Investigational Site | Hokkaido, Japan | Recruiting |
| GSK Investigational Site | Kumamoto, Japan | Recruiting |
| GSK Investigational Site | Mie, Japan | Recruiting |
| GSK Investigational Site | Osaka, Japan | Recruiting |
| GSK Investigational Site | Saitama, Japan | Recruiting |
| GSK Investigational Site | Saitama, Japan | Recruiting |
| GSK Investigational Site | Shizuoka, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07596173